JP2007517060A - 中枢神経系障害又は疾患の治療又は管理のためのサリドマイドを用いた方法及び組成物 - Google Patents

中枢神経系障害又は疾患の治療又は管理のためのサリドマイドを用いた方法及び組成物 Download PDF

Info

Publication number
JP2007517060A
JP2007517060A JP2006547565A JP2006547565A JP2007517060A JP 2007517060 A JP2007517060 A JP 2007517060A JP 2006547565 A JP2006547565 A JP 2006547565A JP 2006547565 A JP2006547565 A JP 2006547565A JP 2007517060 A JP2007517060 A JP 2007517060A
Authority
JP
Japan
Prior art keywords
disease
thalidomide
parkinson
central nervous
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006547565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517060A5 (https=
Inventor
ビー． ゼルディス ジェロメ
エイチ． スチャフェル ペテル
ファレク ヘルベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2007517060A publication Critical patent/JP2007517060A/ja
Publication of JP2007517060A5 publication Critical patent/JP2007517060A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006547565A 2003-12-30 2004-12-27 中枢神経系障害又は疾患の治療又は管理のためのサリドマイドを用いた方法及び組成物 Abandoned JP2007517060A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53386403P 2003-12-30 2003-12-30
PCT/US2004/043925 WO2005065372A2 (en) 2003-12-30 2004-12-27 Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases

Publications (2)

Publication Number Publication Date
JP2007517060A true JP2007517060A (ja) 2007-06-28
JP2007517060A5 JP2007517060A5 (https=) 2007-10-25

Family

ID=34748975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547565A Abandoned JP2007517060A (ja) 2003-12-30 2004-12-27 中枢神経系障害又は疾患の治療又は管理のためのサリドマイドを用いた方法及び組成物

Country Status (11)

Country Link
US (1) US20050182097A1 (https=)
EP (1) EP1704186A4 (https=)
JP (1) JP2007517060A (https=)
KR (1) KR20060128961A (https=)
CN (1) CN1921857A (https=)
AU (1) AU2004311421A1 (https=)
BR (1) BRPI0417913A (https=)
CA (1) CA2551518A1 (https=)
IL (1) IL176453A0 (https=)
NZ (1) NZ548537A (https=)
WO (1) WO2005065372A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
WO2011154739A1 (en) * 2010-06-09 2011-12-15 Generics [Uk] Limited Crystalline forms of thalidomide and processes for their preparation
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
JP6930969B2 (ja) 2015-07-08 2021-09-01 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5739119A (en) * 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
FR2756737B1 (fr) * 1996-12-05 1999-01-08 Rhone Poulenc Rorer Sa Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6423321B2 (en) * 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
US20030185826A1 (en) * 1999-02-24 2003-10-02 Tobinick Edward L. Cytokine antagonists for the treatment of localized disorders
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6982089B2 (en) * 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6537549B2 (en) * 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US20030113318A1 (en) * 1999-02-24 2003-06-19 Tobinick Edward Lewis TNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrhea
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
EP1313460A2 (en) * 1999-11-09 2003-05-28 Darwin Discovery Limited Therapeutic use and formulation of (-)-tramadol
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
DE50304744D1 (de) * 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis

Also Published As

Publication number Publication date
WO2005065372A3 (en) 2006-02-02
KR20060128961A (ko) 2006-12-14
WO2005065372A2 (en) 2005-07-21
EP1704186A2 (en) 2006-09-27
EP1704186A4 (en) 2009-02-04
NZ548537A (en) 2008-08-29
BRPI0417913A (pt) 2007-04-10
CA2551518A1 (en) 2005-07-21
AU2004311421A1 (en) 2005-07-21
CN1921857A (zh) 2007-02-28
IL176453A0 (en) 2006-10-05
US20050182097A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
US20080227816A1 (en) Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
JP2007531770A (ja) 睡眠不全、及び疾患に伴う睡眠不全の治療、予防、又は管理の方法、及びそれに用いる組成物
JP2008520731A (ja) 中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物
JP2007517060A (ja) 中枢神経系障害又は疾患の治療又は管理のためのサリドマイドを用いた方法及び組成物
CN1780616B (zh) 治疗中枢神经系统疾病的选择性细胞因子抑制药物
US20040175382A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
MXPA06007165A (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
HK1100817A (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
US20070190070A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US20170119775A1 (en) Treatment of cognitive disorders
MXPA06007166A (en) Immunomodulatory compounds for the treatment of central nervous system disorders
MXPA06010091A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
HK1102713A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP2016141669A (ja) 慢性骨髄性白血病治療剤
HK1100742A (en) Immunomodulatory compounds for the treatment of central nervous system disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070904

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20091030